Pharmacodynamics of Vildagliptin in Patients With Type 2 Diabetes During OGTT (Q58448401)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442688%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

title

Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442688%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

0 references

0 references

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442688%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Jens Juul Holst

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442688%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

Yan-Ling He

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442688%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Yibin Wang

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442688%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Monica Ligueros-Saylan

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442688%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Julie M Bullock

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442688%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Beth E Dunning

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442688%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

James E Foley

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442688%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

publication date

1 May 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442688%20AND%20SRC:MED&resulttype=core&format=json

The Journal of Clinical Pharmacology

29 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442688%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442688%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

633-641

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442688%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442688%20AND%20SRC:MED&resulttype=core&format=json

The incretin concept today

29 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270006299137

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006299137

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006299137

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006299137

1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006299137

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006299137

Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006299137

Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006299137

Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006299137

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006299137

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006299137

Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006299137

Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006299137

(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006299137

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006299137

21 January 2018

Identifiers

DOI

10.1177/0091270006299137

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442688%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference